MedWatch

Symphogen moves new candidate into clinical phases

The biotech company has taken another step toward the big leagues by sending its second candidate drug into clinical phases. The drug combines two antibodies and will target a number of different cancer types.

Foto: Stine Bidstrup

“The more products you have in clinical phases, the better it is for the company,” Kirsten Drejer, CEO of Symphogen, tells MedWatch after the biotech company announced that it would be initiating clinical trials with a second candidate drug.

That product is Sym015 which combines two antibodies, targeting the MET receptor found on the surface of some cancer cells where it helps them to grow. The idea is to find patients whose tumors exhibit a lot of MET receptors as measured by a special test, which makes them susceptible to the treatment.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Snipr Biome-direktør glæder sig over FDA-særstatus

Med en fast track-status fra den amerikanske lægemiddelmyndighed, FDA, ser Snipr Biomes medstifter og adm. direktør, Christian Grøndahl, frem til mere kommunikation med lægemiddelmyndigheden om kandidaten SNIPR001, der nu potentielt også kan komme hurtigere på markedet.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier